Office: 317- 276-0646
Fax: 317-276-5546
email: lphebus@lilly.com
At the Lilly Research Laboratories, my efforts
are concentrated on neuroscience drug discovery, particularly in the serotonin
and neuropeptide areas. My research interests have recently been
focused on the neural mechanisms of migraine pain. I was involved
in bringing forward a novel compound that blocked the inflammatory effects
of the neuromodulator, substance P. Working as part of a drug discovery
team, we identified a possible role for the 5-HT1F receptor in the
treatment of migraine pain. This effort has led to the clinical testing
of a compound that selectively stimulates 5-HT1F serotonin receptors.
In addition, I have an interest in sensing and
sampling technologies that can be used to better understand brain physiology.
In vivo microdialysis and voltammetry are examples of the approaches we
employ. We also use a novel technique, scanned laser Doppler flowmetry,
to map cortical blood flow under various physiological and pathological
conditions. This methodology provides graphic color images of cortical
blood which can be presented in rapid succession producing an animation-like
effect. Using this imaging technique in animals, the progression
of stroke-induced cortical ischemia can be monitored over time. The ability
to visualize dynamic changes in cortical blood flow helps provide a better
understanding of vascular CNS diseases like stroke.
Publications:
Sang CN, Ramadan NM, Wallihan RG,
Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus
LA, Bleakman D, Ornstein PL, Arnold B, Tepper SJ, Vandenhende F. LY293558,
a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.
Cephalalgia. 2004 Jul;24(7):596-602.
Ramadan NM, Skljarevski V, Phebus LA, Johnson KW. 5-HT1F receptor
agonists in acute migraine treatment: a hypothesis. Cephalalgia. 2003 Oct;23(8):776-85.
Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson
KW, Schaus JM, Ferrari MD. Selective seratonin 1F (5-HT(1F)) receptor agonist
LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001 Oct
13;358(9289):1230-4